Browsing by Yonsei Author : Cho, Byoung Chul

eperson profile image
Cho, Byoung Chul [조병철]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7401747804)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 316

This table browses all dspace content
Issue DateTitleJournal Title
2023A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma ESMO OPEN
2023Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea Cancer Treatment and Research Communications
2023A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer ESMO OPEN
2023Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyLUNG CANCER
2023Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC JOURNAL OF THORACIC ONCOLOGY
2023Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in AsiaJOURNAL OF THORACIC ONCOLOGY
2023Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study JOURNAL OF CLINICAL ONCOLOGY
2023Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study LUNG CANCER
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2023Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset FRONTIERS IN ONCOLOGY
2023Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors ONCOLOGIST
2023Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications CLINICAL LUNG CANCER
2023The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE
2023Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer NATURE COMMUNICATIONS
2023A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation CANCER
2023Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study JOURNAL OF CLINICAL ONCOLOGY
2023Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCCLINICAL CANCER RESEARCH
2023A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataFUTURE ONCOLOGY
2023Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2023Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid TumorsTARGETED ONCOLOGY
2023Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis CANCER RESEARCH AND TREATMENT
2022Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)CLINICAL LUNG CANCER
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
2022Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
2022Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)EUROPEAN JOURNAL OF CANCER
2022Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trialEUROPEAN JOURNAL OF CANCER
2022Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutationEUROPEAN JOURNAL OF CANCER
20222LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)EUROPEAN JOURNAL OF CANCER
2022First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors INVESTIGATIONAL NEW DRUGS
2022Lazertinib: on the Way to Its Throne YONSEI MEDICAL JOURNAL
2022Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer CLINICAL LUNG CANCER
2022Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1 BIOMEDICINE & PHARMACOTHERAPY
2022DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy EXPERIMENTAL AND MOLECULAR MEDICINE
2022Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)CLINICAL CANCER RESEARCH
2022A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancerEXPERT OPINION ON INVESTIGATIONAL DRUGS
2022Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung CancerCLINICAL LUNG CANCER
2022Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC JTO Clinical and Research Reports
2022Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyLANCET ONCOLOGY
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2022Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter TrialJOURNAL OF THORACIC ONCOLOGY
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors JOURNAL OF THORACIC ONCOLOGY
2022Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors CLINICAL CANCER RESEARCH
2022Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer JOURNAL OF CLINICAL ONCOLOGY
2022Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice CLINICAL CANCER RESEARCH
2022Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice CURRENT ONCOLOGY